Savara (SVRA) Goodwill & Intangibles (2011 - 2019)
Savara (SVRA) reported Goodwill & Intangibles of $19.4 million for Q3 2019, down 27.93% year-over-year from $27.0 million in Q3 2018, and little changed on a QoQ basis from $19.4 million in Q2 2019.
Savara (SVRA) has 9 years of Goodwill & Intangibles data on file, last reported at $19.4 million in Q3 2019.
- Quarterly Goodwill & Intangibles fell 27.93% year-over-year to $19.4 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $19.4 million (down 27.93% YoY) and the FY2018 annual result came in at $26.9 million, down 0.61% from the prior year.
- Goodwill & Intangibles was little changed at $19.4 million in Q3 2019 per SVRA's latest filing, from $19.4 million in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $28.3 million in Q3 2017 and bottomed at $3.0 million in Q1 2015.
- The 5-year median for Goodwill & Intangibles is $19.4 million (2019), against an average of $15.9 million.
- The widest annual swing landed in 2015, when Goodwill & Intangibles tumbled 73.98%; it then soared 842.2% in 2017.
- Tracing SVRA's Goodwill & Intangibles over 5 years: stood at $3.0 million in 2015, then gained by 1.46% to $3.1 million in 2016, then jumped by 787.64% to $27.1 million in 2017, then declined by 0.61% to $26.9 million in 2018, then declined by 27.81% to $19.4 million in 2019.
- Per Business Quant, the three latest SVRA Goodwill & Intangibles figures stand at $19.4 million (Q3 2019), $19.4 million (Q2 2019), and $26.8 million (Q1 2019).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 19.43 Mn |
| Jun 30, 2019 | 19.43 Mn |
| Mar 31, 2019 | 26.80 Mn |
| Dec 31, 2018 | 26.92 Mn |
| Sep 30, 2018 | 26.96 Mn |
| Jun 30, 2018 | 26.99 Mn |
| Mar 31, 2018 | 27.17 Mn |
| Dec 31, 2017 | 27.08 Mn |
| Sep 30, 2017 | 28.33 Mn |
| Jun 30, 2017 | 28.22 Mn |
| Mar 31, 2017 | 3.01 Mn |
| Dec 31, 2016 | 3.05 Mn |
| Sep 30, 2016 | 3.01 Mn |
| Jun 30, 2016 | 3.01 Mn |
| Mar 31, 2016 | 3.01 Mn |
| Dec 31, 2015 | 3.01 Mn |
| Sep 30, 2015 | 11.56 Mn |
| Jun 30, 2015 | 11.56 Mn |
| Mar 31, 2015 | 3.01 Mn |
| Dec 31, 2014 | 11.56 Mn |
| Sep 30, 2014 | 11.56 Mn |
| Jun 30, 2014 | 11.56 Mn |
| Mar 31, 2014 | 11.56 Mn |
| Dec 31, 2013 | 9.56 Mn |
| Sep 30, 2013 | 3.01 Mn |
| Jun 30, 2013 | 3.01 Mn |
| Mar 31, 2013 | 3.01 Mn |
| Dec 31, 2012 | 3.01 Mn |
| Sep 30, 2012 | 3.01 Mn |
| Jun 30, 2012 | 3.01 Mn |
| Mar 31, 2012 | 3.01 Mn |
| Dec 31, 2011 | 3.01 Mn |
| Sep 30, 2011 | 403,795.00 |
| Jun 30, 2011 | 403,795.00 |